Home Chemicals & Materials Specialty Chemicals Montelukast Intermediate Market

Montelukast Intermediate Market Size, Share & Trends Analysis Report By Type (GMP, Non-GMP), By Applications (Asthma, Bronchospasm, Allergic Rhinitis, Urticaria), By End-User (Pharmaceutical and Biotechnological Companies, Laboratories, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Anantika Sharma | Format: | Report Code: SR296DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Montelukast Intermediate Market, By Type 2022-2034 (USD MILLION/ Units)
    1. GMP
    2. Non-GMP
  2. Montelukast Intermediate Market, By Applications 2022-2034 (USD MILLION/ Units)
    1. Asthma 
    2. Bronchospasm
    3. Allergic Rhinitis
    4. Urticaria
  3. Montelukast Intermediate Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical and Biotechnological Companies
    2. Laboratories
    3. Others
  4. Regional Montelukast Intermediate Market
    1. North America
      1. North America Montelukast Intermediate Market By Type 2022-2034 (USD MILLION/ Units)
        1. GMP
        2. Non-GMP
      2. North America Montelukast Intermediate Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Asthma 
        2. Bronchospasm
        3. Allergic Rhinitis
        4. Urticaria
      3. North America Montelukast Intermediate Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnological Companies
        2. Laboratories
        3. Others
      4. U.S.
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      5. Canada
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
    2. Europe
      1. Europe Montelukast Intermediate Market By Type 2022-2034 (USD MILLION/ Units)
        1. GMP
        2. Non-GMP
      2. Europe Montelukast Intermediate Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Asthma 
        2. Bronchospasm
        3. Allergic Rhinitis
        4. Urticaria
      3. Europe Montelukast Intermediate Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnological Companies
        2. Laboratories
        3. Others
      4. U.K.
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      5. Germany
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      6. France
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      7. Spain
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      8. Italy
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      9. Russia
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      10. Nordic
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      11. Benelux
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      12. Rest of Europe
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
    3. APAC
      1. APAC Montelukast Intermediate Market By Type 2022-2034 (USD MILLION/ Units)
        1. GMP
        2. Non-GMP
      2. APAC Montelukast Intermediate Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Asthma 
        2. Bronchospasm
        3. Allergic Rhinitis
        4. Urticaria
      3. APAC Montelukast Intermediate Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnological Companies
        2. Laboratories
        3. Others
      4. China
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      5. Korea
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      6. Japan
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      7. India
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      8. Australia
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      9. Singapore
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      10. Taiwan
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      11. South East Asia
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      12. Rest of Asia-Pacific
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
    4. Middle East and Africa
      1. Middle East and Africa Montelukast Intermediate Market By Type 2022-2034 (USD MILLION/ Units)
        1. GMP
        2. Non-GMP
      2. Middle East and Africa Montelukast Intermediate Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Asthma 
        2. Bronchospasm
        3. Allergic Rhinitis
        4. Urticaria
      3. Middle East and Africa Montelukast Intermediate Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnological Companies
        2. Laboratories
        3. Others
      4. UAE
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      5. Turkey
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      6. Saudi Arabia
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      7. South Africa
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      8. Egypt
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      9. Nigeria
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      10. Rest of MEA
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
    5. LATAM
      1. LATAM Montelukast Intermediate Market By Type 2022-2034 (USD MILLION/ Units)
        1. GMP
        2. Non-GMP
      2. LATAM Montelukast Intermediate Market By Applications 2022-2034 (USD MILLION/ Units)
        1. Asthma 
        2. Bronchospasm
        3. Allergic Rhinitis
        4. Urticaria
      3. LATAM Montelukast Intermediate Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnological Companies
        2. Laboratories
        3. Others
      4. Brazil
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      5. Mexico
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      6. Argentina
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      7. Chile
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      8. Colombia
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
      9. Rest of LATAM
        1. GMP
        2. Non-GMP
        3. Asthma 
        4. Bronchospasm
        5. Allergic Rhinitis
        6. Urticaria
        7. Pharmaceutical and Biotechnological Companies
        8. Laboratories
        9. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.